Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers
Matthew J. Baggott, Kathleen J. Garrison, Jeremy Coyle, Gantt P. Galloway, Allan J. Barnes, Marilyn A. Huestis, John Mendelson
Journal of Psychoactive Drugs March 15, 2019 DOI: 10.1080/02791072.2019.1593560 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Within-subjects, double-blind, placebo-controlled study Peer reviewed |
|---|---|
| Population | Human participants |
| Intervention | 1.4 mg/kg oral racemic MDA |
| Dose | 1.4 mg/kg oral racemic MDA |
| Keywords | Amphetamine Pharmacology |
| Citations | 20 |
| Key points | MDA produces longer-lasting subjective effects than MDMA, likely due to pharmacodynamic differences rather than pharmacokinetics. |
Abstract
Entactogens such as 3,4-Methylenedioxymethamphetamine (MDMA, "molly", "ecstasy") appear to have unusual, potentially therapeutic, emotional effects. Understanding their mechanisms can benefit from clinical experiments with related drugs. Yet the first known drug with such properties, 3,4-Methylenedioxyamphetamine (MDA), remains poorly studied and its pharmacokinetics in humans are unknown. We conducted a within-subjects, double-blind, placebo-controlled study of 1.4 mg/kg oral racemic MDA and compared results to those from our prior similar studies with 1.5 mg/kg oral racemic MDMA. MDA was well-tolerated by participants. MDA induced robust increases in heart rate and blood pressure and increased cortisol and prolactin to a similar degree as MDMA. MDA self-report effects shared features with MDMA as well as with classical psychedelics. MDA self-report effects lasted longer than those of MDMA, with MDA effects remaining elevated at 8 h while MDMA effects resolved by 6 h. Cmax and AUC0-∞ for MDA were 229 ± 39 (mean ± SD) and 3636 ± 958 µg/L for MDA and 92 ± 61 and 1544 ± 741 µg/L for the metabolite 4-hydroxy-3-methoxyamphetamine (HMA). There was considerable between-subject variation in MDA/HMA ratios. The similarity of MDA and MDMA pharmacokinetics suggests that the greater duration of MDA effects is due to pharmacodynamics rather than pharmacokinetics.